Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
yahoo.com
news
2022-10-20 11:00:00

− Collaboration Provides Takeda an Exclusive License to Develop and Commercialize ZED1227/TAK-227 in the United States and Other Countries Outside of Europe, Canada, Australia and China

− Agreement Adds Third Investigational Therapy to Takeda's Pipeline for the Potential Treatment of Celiac Disease

OSAKA, Japan & FREIBURG, Germany & DARMSTADT, Germany, October 20, 2022--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK), Zedira and Dr. Falk Pharma GmbH today announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac disease.
